Melissa Johnson, MD
Director, Lung Cancer Research
Dr. Johnson joined Sarah Cannon in 2014 and serves as the director of lung cancer research. Her responsibilities include leading the lung cancer clinical trial portfolio across the Sarah Cannon network. Dr. Johnson continues to work in early phase drug development as well as lead the solid tumor immune effector cellular therapy program at Sarah Cannon. She also currently serves as the chair of the Cancer Committee at TriStar Centennial Medical Center in Nashville, Tenn.
Dr. Johnson received her undergraduate degree from the University of North Carolina, Chapel Hill where she was a Morehead Scholar, and her medical degree from the University of Pennsylvania. She completed her residency in internal medicine at New York Presbyterian/Weill Cornell Medical Center and her fellowship in medical oncology and hematology at Memorial Sloan Kettering Cancer Center where she also served as chief fellow for one year. She spent four years as a faculty member at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Feinberg School of Medicine, where she was a founding member of the Northwestern Medical Developmental Therapeutics Institute.
She is board certified in internal medicine and medical oncology. Additionally, she is a partner of Tennessee Oncology, PLLC.